Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

• Status: Completed
• Trial end date: 2013-05-01

Summary

This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with either FCR or BR in subjects with relapsed or refractory chronic lymphocytic leukemia.

• Phase: Phase 1

Details

• Lead Sponsor: AbbVie (prior sponsor, Abbott)
• Collaborator: Genentech, Inc.
• Treatments: Bendamustine Hydrochloride; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Navitoclax; Rituximab; Vidarabine